XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2009 by Odense University Hospital.
Recruitment status was  Active, not recruiting
Information provided by:
Odense University Hospital
ClinicalTrials.gov Identifier:
First received: September 13, 2005
Last updated: October 16, 2009
Last verified: October 2009

XELOX (Capecitabine and Oxaliplatin) is an effective and convenient regimen for patients with metastatic colorectal cancer. Chronomodulated therapy may reduce toxicity. Patients will be randomized to standard XELOX (Capecitabine 1000 mg/m² in the morning and 1000 mg/m² in the evening days 1-14 and short term Oxaliplatin 130 mg/m² day 1 in 30 minutes) or chronomodulated XELOX (Capecitabine 400 mg/m² in the morning and 1600 mg/m² in the evening days 1-14 and short term Oxaliplatin 130 mg/m² day 1 in 30 minutes).

Bloodsamples will be collected and frozen and later examined for potential predictive factors

Condition Intervention Phase
Drug: Oxaliplatin (Eloxatin)
Drug: Capecitabine (Xeloda)
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: XELOX III. Capecitabine (Xeloda) in Combination With Oxaliplatin (Eloxatin) as First-line Treatment of Patients With Advanced or Metastatic Colorectal Cancer. A Randomized Phase II Study

Resource links provided by NLM:

Further study details as provided by Odense University Hospital:

Primary Outcome Measures:
  • Toxicity: before treatment (each 3 weeks) and by SAE (Serious Adverse Event)

Secondary Outcome Measures:
  • Physical examination: before treatment (each 3 weeks)
  • Performance status: before treatment (each 3 weeks)
  • Haematology: before treatment (each 3 weeks)
  • Tumor biology: after 1st treatment, every 9th weeks herafter
  • Biochemistry: after every 3rd treatment (each 9th weeks)
  • Tumor assesment: after every 3rd treatment (each 9th weeks)

Estimated Enrollment: 116
Study Start Date: February 2004
Estimated Study Completion Date: October 2008

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological proven adenocarcinoma of the colon or rectum
  • Measurable or non-measurable disease
  • Performance status 0-2
  • Adequate renal and hepatic functions
  • Adjuvant chemotherapy must have ended 180 days before inclusion
  • Written informed consent prior to randomization

Exclusion Criteria:

  • Prior treatment with Eloxatin or Xeloda
  • Peripheral neuropathy
  • Evidence of CNS metastasis
  • Other serious illness or medical conditions (including contraindication to 5 FU e.g.: angor, myocardial infarction within 6 months)
  • Past history of malignant neoplasm within the past five years, except curatively treated non melanoma skin cancer
  • Administration of any other experimental drug under investigation within 2 weeks before randomisation
  • Pregnant or breast feeding women
  • Fertile patients must use adequate contraceptives
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00212615

Department of Oncology, Esbjerg Hospital
Esbjerg, Denmark, 6700
Department of Oncology, Herlev University Hospital
Herlev, Denmark, 2730
Department of Oncology, Herning Hospital
Herning, Denmark, 7400
Department of Oncology, Hilleroed Hospital
Hilleroed, Denmark, 3400
Department of Oncology, Naestved Hospital
Naestved, Denmark, 4700
Department of Oncology, Roskilde Hospital
Roskilde, Denmark, 4000
Department of Oncology, Radiumhemmet
Stockholm, Sweden, 100 26
Department of Oncology, Uppsala University Hospital
Uppsala, Sweden, 751 85
Sponsors and Collaborators
Odense University Hospital
Principal Investigator: Per Pfeiffer, MD Department of Oncology, Odense University Hospital
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00212615     History of Changes
Other Study ID Numbers: XELOX III  KFE 03.17 
Study First Received: September 13, 2005
Last Updated: October 16, 2009
Health Authority: Denmark: Central Scientific Ethical Committee

Keywords provided by Odense University Hospital:
Colorectal neoplasm
Capecitabine (Xeloda)
Oxaliplatin (Eloxatin)
Advanced disease
Metastatic disease
First-line treatment
Phase II study

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms by Site
Rectal Diseases
Antimetabolites, Antineoplastic
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 23, 2016